GlassScriptPhysician profile
Jonathan P Anderson
NPI 1588664916
$3,241.75
in general payments reported to CMS, 2019-2025
30 companies · $58.52 in 2025
The $58.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,736 · 2020: $410 · 2024: $36.78 · 2025: $58.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $547.47 | 2019-2020 | |
| Pfizer INC. | $472.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $297.70 | 2019-2020 | |
| Amgen INC. | $294.15 | 2019-2020 | |
| Novo Nordisk INC | $199.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $172.01 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.01 | 2019 | |
| Astellas Pharma US INC | $123.38 | 2019-2020 | |
| Lilly USA, LLC | $122.93 | 2019-2024 | Mounjaro, Zepbound |
| Amag Pharmaceuticals, INC. | $97.21 | 2019-2020 | |
| Allergan, INC. | $95.00 | 2019 | |
| Kaleo, INC. | $85.45 | 2019-2020 | |
| Amarin Pharma, INC. | $68.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.17 | 2019-2020 | |
| Abbvie INC. | $46.89 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $45.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.83 | 2019-2024 | |
| Therapeuticsmd, INC. | $38.34 | 2019 | |
| Sanofi Pasteur INC. | $37.34 | 2019 | |
| Dexcom, INC. | $34.38 | 2025 | Dexcom G6 Transmitter |
| Nalpropion Pharmaceuticals LLC | $27.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.41 | 2019 | |
| Alk-Abello, INC | $24.14 | 2025 | Neffy |
| Abbott Laboratories | $24.08 | 2019 | |
| Ibsa Pharma INC. | $20.74 | 2019 | |
| Avanir Pharmaceuticals, INC. | $20.60 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.77 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.